Antimicrobial activity of a new fluoroquinolone, DU-6859a, against quinolone-resistant clinical isolates of Neisseria gonorrhoeae with genetic alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue 2, 1997, Pages 247-249

  Deguchi, Takashi ^a   Yasuda, Mitsuru ^a   Nakano, Masahiro ^a   Kanematsu, Emiko ^a   Ozeki, Shigehiko ^a   Ishihara, Satoshi ^a   Saito, Isao ^b   Kawada, Yukimichi ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO KYOSAI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; DRUG POTENCY; GONOCOCCAL URETHRITIS; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE;

ANTI-INFECTIVE AGENTS; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; NEISSERIA GONORRHOEAE; QUINOLONES;

EID: 0031059176     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.2.247     Document Type: Article

References (10)

1. Centers for Disease Control. (1993). 1993 sexually transmitted diseases treatment guidelines. Morbidity and Mortality Weekly Report 42, Suppl. RR-14, 57-9.
2. Tapsall, J. W., Shultz, T. R., Lovett, R. & Munro, R. (1992). Failure of 500 mg ciprofloxacin therapy in male urethral gonorrhoea. Medical Journal of Australia 156, 143.
3. Tapsall, J. W., Limnios, E. A., Thacker, C., Donovan, B., Lynch, S. D., Kirby, L. J. et al. (1995). High-level quinolone resistance in Neisseria gonorrhoeae: a report of two cases. Sexually Transmitted Diseases 22, 310-1.
4. Belland, R. J., Morrison, S. G., Ison, C. & Huang, W. M. (1994). Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Molecular Microbiology 14, 371-80.
5. Deguchi, T., Yasuda, M., Nakano, M., Ozeki, S., Ezaki, T., Saito, I. et al. (1996). Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DMA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles. Antimicrobial Agents and Chemotherapy 40, 1020-3.
6. Sato, K., Hoshino, K., Tanaka, M., Hayakawa, I. & Osada, Y. (1992). Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrobial Agents and Chemotherapy 36, 1494-8.
7. Kitamura, A., Hoshino, K., Kimura, Y., Hayakawa, I. & Sato, K. (1995). Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DMA gyrase mutants of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 39, 1467-71.
8. National Committee for Clinical Laboratory Standards. (1993). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Third Edition: Approved Standard M7-A3. NCCLS, Villanova, PA.
9. Aoki, H., Tachibana, M., Tanaka, M., Okazaki, O. & Hakusui, H. (1993). DU-6859a, a novel quinolone: identification of the main metabolite in rats. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1993. Abstract 1001, p. 302. American Society for Microbiology, Washington, DC.
10. Nakashima, M., Uematsu, T., Kosuge, K., Umemura, K., Hakusui, H. & Tanaka, M. (1995). Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrobial Agents and Chemotherapy 39, 170-4.